Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.

Description

The aim of this clinical trial was to investigate the efficacy and safety of rosiglitazone to prevent the development of atherosclerosis in saphenous vein graft (SVG) and to modify the global cardiometabolic risk profile. This multicentre trial recruted 193 post-coronary artery bypass grafting (CABG) patients with type 2 diabetes. The results of this study reported that rosiglitazone did not have a statistically significant effect on atherosclerosis progression in SVG even though it had a favourable impact on the cardiometabolic risk profile. More specifically, improvements in insulin resistance, lipid and inflammatory profile as well as adiponectin levels were observed in rosiglitazone-treated patients. In addition, the weight gain induced by rosiglitazone was found to be caused by an increase in subcutaneous adiposity with no change in deleterious intra-abdominal (visceral) adiposity. These results suggest that the beneficial effect of rosiglitazone on the cardiometabolic risk profile could be partly explained by changes in subcutaneous adiposity.